Dariusz Pawlak publikacje

Wykaz prac opublikowanych w latach 2016-1989
(dane z dnia 2016-11-28 wg. http://biblioteka.umb.edu.pl/expertus/analiza.html)
współczynnik Hirscha = 19
IF = 202
punktacja ministerstwa = 1929

2016 rok

PAWLAK D, Oksztulska-Kolanek E, Znorko B, Domaniewski T, Rogalska J, Roszczenko A, Brz├│ska MM,
Pryczynicz A, Kemona A, Pawlak K.: The association between elevated levels of peripheral serotonin and its
Metabolite - 5-Hydroxyindoleacetic Acid and Bone Strength and Metabolism in Growing Rats with Mild
experimental chronic kidney disease. PLoS One. 2016 Oct 6;11(10):e0163526. doi:
10.1371/journal.pone.0163526.

Kalaska B, Ciborowski M, Domaniewski T, Czyzewska U, Godzien J, Miltyk W, Kretowski A, PAWLAK D.: Serum
metabolic fingerprinting after exposure of rats to quinolinic acid. J Pharm Biomed Anal. 131, 175-182, 2016. doi:
10.1016/j.jpba.2016.08.024.

Tankiewicz-Kwedlo A, Hermanowicz J, Sura┼╝ynski A, Ro┼╝kiewicz D, Pryczynicz A, Domaniewski T, Pawlak K,
Kemona A, PAWLAK D.: Erythropoietin accelerates tumor growth through increase of erythropoietin receptor
(EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts. Mol Cell Biochem. 2016
Oct;421(1-2):1-18. doi: 10.1007/s11010-016-2779-x.

Jasiewicz M., Moniuszko M., PAWLAK D., Knapp M., Rusak M., Kazimierczyk R., Musial W.J., Dabrowska M,
Kaminski K.A.: Activity of the kynurenine pathway and its interplay with immunity in patients with pulmonary
arterial hypertension. Heart 102(3), 230-237, 2016

Kalaska B, Kaminski K, Miklosz J, Yusa SI, Sokolowska E, Blazejczyk A, Wietrzyk J, Kasacka I, Szczubialka K,
PAWLAK D, Nowakowska M, Mogielnicki A.: Heparin-binding copolymer reverses effects of unfractionated
heparin, enoxaparin, and fondaparinux in rats and mice. Transl. Res. 2016 Jul 5 S1931-5244(16)30102-5. doi:
10.1016/j.trsl.2016.06.009.

Sokolowska E, Kalaska B, Kaminski K, Lewandowska A, Blazejczyk A, Wietrzyk J, Kasacka I, Szczubialka K,
PAWLAK D, Nowakowska M, Mogielnicki A. The toxicokinetic profile of Dex40-GTMAC3-a novel polysaccharide
candidate for reversal of unfractionated heparin. Front. Pharmacol. 2016 Mar 17;7:60.
doi:10.3389/fphar.2016.00060

Karbowska M, Kamiński T, PAWLAK D.: Methods of reducing the level of indoxyl sulfate - one of the most potent
protein-bound uremic toxins. Toxin Reviews 1-9, 2016, DOI: 10.1080/15569543.2016.1222442

PAWLAK D, Kamiński T.: Pharmacological basis for therapy of people who stutter - past, present and future. In: A
new approach to stuttering. Diagnosis and therapy. [Red.] Zbigniew Tarkowski. New York : Nova Biomedical 95-
116, 2016


2015 rok

Michalowska M., Znorko B., Kaminski T., Oksztulska-Kolanek E., PAWLAK D.: New insights into tryptophan and
its metabolites in the regulation of bone metabolism. J. Physiol. Pharmacol. 66(6), 779-791, 2015

Pawlak K., Mysliwiec M., PAWLAK D.: Endocan--the new endothelial activation marker independently associated
with soluble endothelial adhesion molecules in uraemic patients with cardiovascular disease. Clin. Biochem.
48(6), 425-430, 2015

Michałowska. M, Znorko B., Oksztulska-Kolanek E., Kamiński T., PAWLAK D.: A view at monoclonal antibodies in
therapy of osteoporosis. Pol. Annals Med. 22(2), 149-154, 2015

Kałaska B., Kamiński K., Sokołowska E., Czaplicki D., Kujdowicz M., Stalińska K., Bereta J., Szczubiałka K.,
PAWLAK D., Nowakowska M., Mogielnicki A.: Nonclinical evaluation of novel cationically modified polysaccharide
antidotes for unfractionated heparin. PLoS ONE 10, 3, 2015 e0119486

Kamiński T., PAWLAK D.: Leki generyczne we współczesnej farmakoterapii. Farm. Pol. 70(6), 321-326, 2014

2014 rok

Pawlak K., Mysliwiec M., PAWLAK D.: oxLDL - the molecule linking hypercoagulability with the presence of
cardiovascular disease in hemodialyzed uraemic patients. Thromb. Res. 134(3), 711-716, 2014

Pawlak K., My┼Ťliwiec M., PAWLAK D.: Effect of diabetes and oxidative stress on plasma CCL23 levels in patients
with severe chronic kidney disease. Pol. Arch. Med. Wewn. 124(9), 459-466, 2014

2013 rok

Pawlak K., Mysliwiec M., PAWLAK D.: Oxidized low-density lipoprotein (oxLDL) plasma levels and oxLDL to LDL
ratio - are they real oxidative stress markers in dialyzed patients? Life Sci. 92 (4-5), 253-258, 2013

Pawlak K., Ro┼╝kiewicz D., Mysliwiec M., PAWLAK D.: YKL-40 in hemodialyzed patients with and without
cardiovascular complications - The enhancement by the coexistence of the seropositivity against hepatitis C virus
infection. Cytokine 62 (1), 75 -80, 2013

2012 rok

Pawlak K, Mysliwiec M, PAWLAK D.: Oxidized LDL to autoantibodies against oxLDL ratio - the new biomarker
associated with carotid atherosclerosis and cardiovascular complications in dialyzed patients. Atherosclerosis
224 (1), 252-257, 2012

Pawlak K, Mysliwiec M, PAWLAK D.: Hyperhomocysteinemia and the presence of cardiovascular disease are
associated with kynurenic acid levels and carotid atherosclerosis in patients undergoing continuous ambulatory
peritoneal dialysis. Thromb. Res. 129 (6), 704-709, 2012

Pawlak K, Mysliwiec M, PAWLAK D.: The alteration in Cu/Zn superoxide dismutase and adhesion molecules
concentrations in diabetic patients with chronic kidney disease: the effect of dialysis treatment. Diabet. Res. Clin.
Pract. 98, 264-270, 2012

Pawlak K, Ulazka B., Mysliwiec M, PAWLAK D.: Vascular endothelial growth factor and uPA/suPAR system in
early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis?
Translat. Res. 160 (5), 346-354, 2012

2011 rok

Pawlak K, Mysliwiec M, PAWLAK D.: Peripheral blood level alterations of MMP-2 and MMP-9 in patients with
chronic kidney disease on conservative treatment and on hemodialysis. Clin. Biochem. 44, 838-843, 2011

Pawlak K, Mysliwiec M, PAWLAK D.: Interleukin-21 in hemodialyzed patients: Association with the etiology of
chronic kidney disease and the seropositivity against hepatitis C virus infection. Clin. Biochem. 44, 1416-1420,
2011
2010 rok

Pawlak K., My┼Ťliwiec M., PAWLAK D.: Kynurenine pathway - a new link between endothelial dysfunction and
carotid atherosclerosis in chronic kidney disease patients. Adv. Med. Sci. 55(2), 196-203, 2010

Pawlak K., Tankiewicz J., Mysliwiec M., PAWLAK D.: Systemic Levels of MMP2/TIMP2 and Cardiovascular Risk
in CAPD Patients. Nephron Clin. Pract. 115(4), c251-c258, 2010

Pawlak K., Buraczewska-Buczko A., Mysliwiec M., PAWLAK D.: Hyperfibrinolysis, uPA/suPAR system,
kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative
treatment. Am. J. Med. Sci. 339 (1), 5-9, 2010

Pawlak K., Mysliwiec M., PAWLAK D.: Haemostatic system, biochemical profiles, kynurenines and the prevalence
of cardiovascular disease in peritoneally dialyzed patients. Thromb. Res. 125 (2), 40-45, 2010

Tankiewicz-Kwedlo A., PAWLAK D., Domaniewski T., Buczko W.: Erythropoietin increases Epo and EpoR
expression in DLD-1 cells. Pol. Ann. Med. 17 (1), 16-24, 2010

Tankiewicz-Kwedlo A, PAWLAK D, Domaniewski T, Buczko W.: Effect of erythropoietin, 5-fluorouracil and SN-38
on the growth of DLD-1 cells. Pharmacol. Rep. 62(5), 926-937, 2010

Pawlak K, Mysliwiec M, PAWLAK D.: Impact of residual renal function and HCV seropositivity on plasma
CD40/CD40L system and oxidative status in haemodialysis patients. Clin. Biochem. 43 (18), 1393-1398, 2010

Pawlak K, Mysliwiec M, PAWLAK D.: Hepatitis C virus seropositivity and TNF superfamily receptors: sCD40,
sFas--the new putative determinants of endothelial dysfunction in haemodialysis patients. Thromb. Res. 126 (5),
393-398, 2010

Gulaj E, Pawlak K, Bien B, PAWLAK D.: Kynurenine and its metabolites In Alzheimer's disease patients. Adv.
Med. Sci. 55(2), 204-211, 2010

Pawlak K, Kowalewska A, Mysliwiec M, PAWLAK D.: 3-hydroxyanthranilic acid is independently associated with
monocyte chemoattractant protein-1 (CCL2) and macrophage inflammatory protein-1beta (CCL4) in patients with
chronic kidney disease. Clin. Biochem. 43 (13-14), 1101-1106, 2010
2009 rok

Pawlak K., Kowalewska A., Mysliwiec M., PAWLAK D.: Kynurenine and its metabolites-kynurenic acid and
anthranilic acid are associated with soluble endothelial adhesion molecules and oxidative status in patients with
chronic kidney disease. Am. J. Med. Sci. 338 (4), 293-300, 2009

Buczko P., Szarmach I.J., Kasacka I., PAWLAK D.: The concentration of 3-HKYN in saliva of patients with fixed
orthodontic appliances. Pol. J. Environ. Stud. 18, 128-131, 2009

Pawlak K, Domaniewski T, Mysliwiec M, PAWLAK D. Kynurenines and oxidative status are independently
associated with thrombomodulin and von Willebrand factor levels in patients with end-stage renal disease.
Thromb. Res. 124 (4), 452-457, 2009

Pawlak K., Brzosko S., Mysliwiec M., PAWLAK D.: Kynurenine, quinolinic acid-the new factors linked to carotid
atherosclerosis in patients with end-stage renal disease. Atherosclerosis 204 (2), 561-566, 2009

Pawlak K., Domaniewski T., Mysliwiec M., PAWLAK D.: The kynurenines are associated with oxidative stress,
inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease.
Atherosclerosis. 204 (1), 309-314, 2009

Pawlak K., Mysliwiec M., PAWLAK D.: Hypercoagulability is independently associated with kynurenine pathway
activation in dialysed uraemic patients. Thromb. Haemost. 102 (1), 49-55, 2009

Pawlak K., Tankiewicz J., Mysliwiec M., PAWLAK D.: Tissue factor/its pathway inhibitor system and kynurenines
in chronic kidney disease patients on conservative treatment. Blood Coagul. Fibrinolysis 20, 590-594, 2009

My┼Ťliwiec P., My┼Ťliwiec H., PAWLAK D., Pawlak K., Buczko W., Baltaziak M., Dadan J.: Tryptophan metabolism
in experimental necrotizing acute pancreatitis. Folia Histochemica et Cytobiologica
47, 231-236, 2009
My┼Ťliwiec P., My┼Ťliwiec H., PAWLAK D., Dadan J., Buczko W., Pawlak K.: Tryptophan and its metabolites in renal
allograft recipients. Przegl. Lek. 66 (3), 115-118, 2009
2008 rok

Pawlak K., PAWLAK D., My┼Ťliwiec M.: Urokinase-type plasminogen activator and metalloproteinase-2 are
independently related to the carotid atherosclerosis in haemodialysis patients. Thromb. Res. 121 (4), 543-548,
2008

My┼Ťliwiec H., PAWLAK D., Flisiak I., My┼Ťliwiec P., My┼Ťliwiec M., Chodynicka B.: Wybrane metabolity kinureniny a
┼Ťwi─ůd mocznicowy. Przegl. Dermatol. 95 (1), 33-36, 2008

Pawlak K., PAWLAK D., Mysliwiec M.: Effects of long-term erythropoietin therapy on fibrinolytic system in
haemodialyzed patients. Thromb. Res. 121 (6), 787-791, 2008

Pawlak K., Mysliwiec M., PAWLAK D.: The urokinase-type plasminogen activator/its soluble receptor system is
independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients.
Thromb. Res. 122, 328-335, 2008

Pawlak J., Dzięcioł J., Mantur M., PAWLAK D.: Megakaryocytes and platelets in experimentally induced
renovascular hypertension (2K1C) in rats = Megakariocyty i p┼éytki w do┼Ťwiadczalnym nadci┼Ťnieniu naczyniowonerkowym
(2K1C) u szczur├│w. Post. Hig. Med. Do┼Ťwiad. 62, 241-248, 2008

Pawlak K., Mysliwiec M., PAWLAK D.: Oxidative stress, phosphate and creatinine levels are independently
associated with vascular endothelial growth factor levels in patients with chronic renal failure. Cytokine 43, 98-
101, 2008

Pawlak K., Zolbach K., Borawski J., Mysliwiec M., Kovalchuk O., Chyczewski L., PAWLAK D.: Chronic viral
hepatitis C, oxidative stress and the coagulation/fibrinolysis system in haemodialysis patients. Thromb. Res. 123
(1), 166-170, 2008

2007 rok

Gu┼éaj E., PAWLAK D.: Niedokrwisto┼Ť─ç. Farm. Pol. 63 (1), 3-10, 2007

Pawlak K., PAWLAK D.: Placebo niedowarto┼Ťciowana psychoterapia? Gazeta Farmaceutyczna 4, 46-49, 2007

Pawlak K., PAWLAK D., Mysliwiec M.: Impaired renal function and duration of dialysis therapy are associated
with oxidative stress and proatherogenic cytokine levels in patients with end-stage renal disease. Clin. Biochem.
40 (1-2), 81-85, 2007

Pawlak K., PAWLAK D., Mysliwiec M.: Excess soluble urokinase-type plasminogen activator receptor in the
plasma of dialysis patients correlates with increased fibrinolytic activity. Thromb. Res. 119 (4), 475-480, 2007

Pawlak K., PAWLAK D., Mysliwiec M.: Serum matrix metalloproteinase-2 and increased oxidative stress are
associated with carotid atherosclerosis in hemodialyzed patients. Atherosclerosis 190 (1), 199-204, 2007

Pawlak K., PAWLAK D., Mysliwiec M.: Long-term erythropoietin therapy does not affect endothelial markers,
coagulation activation and oxidative stress in haemodialyzed patients. Thromb. Res. 120 (6), 797-803, 2007

Pawlak K., PAWLAK D., Mysliwiec M.: Long-term erythropoietin therapy does not affect metalloproteinases and
their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients. Am. J. Nephrol. 27 (3), 221-
225, 2007

Pawlak K., PAWLAK D., Mysliwiec M.: Tissue factor and urokinase-type plasminogen activator system are related
to the presence of cardiovascular disease in hemodialysis patients. Thromb. Res. 120 (6), 871-876, 2007

Pawlak K., Mysliwiec M., PAWLAK D.: Chronic viral hepatitis and iron affect the plasma levels of LIGHT--a new
member of the TNF superfamily in uraemic haemodialyzed patients. Cytokine 39 (3), 201-206, 2007

Pawlak K., PAWLAK D., Mysliwiec M.: LIGHT- a new member of the TNF superfamily in the plasma, dialysate
and urine of uremic patients; the impact of residual diuresis and presence of viral hepatitis. Clin. Biochem. 40
(16-17), 1240-1244, 2007
Buczko P., Tankiewicz-Kwedlo A., Buraczewska A., My┼Ťliwiec M., PAWLAK D.: Accumulation of kynurenine
pathway metabolites in saliva and plasma of uremic patients. Pharmacol. Rep. 59 (1), 199-204, 2007

Szarmach I., Buczko P., Tankiewicz-Kwedlo A., Kasacka I., Tankiewicz J., PAWLAK D.: The concentration of
kynurenine and anthranilic acid in saliva of patients with fixed orthodontic appliances. Pol. J. Environ. Stud. 16
(2), 125-127, 2007

Tankiewicz-Kwedlo A., Buczko P., Dziemiańczyk-Pakiela D., Szarmach I., Grabowska S., Topczewska-Bruns J.,
PAWLAK D.: Tryptophan metabolism in patients with oral squamous cell carcinoma. Pol. J. Environ. Stud. 16
(2), 120-124, 2007

Pawlak K., PAWLAK D., Mysliwiec M.: Erythropoietin therapy decreased tissue factor, its pathway inhibitor, and
oxidative stress in peritoneal dialysis patients with diabetes. Nephron Clin. Pract. 107 (1), c20-c25, 2007

Pawlak K., PAWLAK D., Mysliwiec M.: Association between tissue factor, its pathway inhibitor and oxidative
stress in peritoneal dialysis patients. Blood Coagul. Fibrinolysis 18 (5), 467-471, 2007

2006 rok

Langfort J., Barańczuk E., PAWLAK D., Chalimoniuk M., Lukacova N., Marsala J., Górski J.: The effect of
endurance training on regional serotonin metabolism in the brain during early stage of detraining period in the
female rat. Cell Mol. Neurobiol. 26 (7-8), 1327-1342, 2006

Buczko P., Stokowska W., G├│rska M., Kucharewicz I., PAWLAK D., Buczko W.: Tryptophan metabolites via
kynurenine pathway in saliva of diabetic patients. Dent. Med. Problems 43 (1), 21-25, 2006

2005 rok

Tankiewicz A., PAWLAK D., Pawlak K., Szewc D., My┼Ťliwiec M., Buczko W.: Anthranilic acid-uraemic toxin
damaged red cell's membrane. Int. Urol. Nephrol. 37 (3), 621-627, 2005

PAWLAK D., Brzóska M., Zwierz K., Stypułkowska A., Moniuszko-Jakoniuk J.: Can kynurenine pathway
tryptophan metabolites be used to monitor cadmium exposure? Pol. J. Environ. Stud. 14 (2), 209-215, 2005

PAWLAK D., Brzóska M., Moniuszko-Jakoniuk J., Stypułkowska A., Zwierz K.: Effect of cadmium on the
peripheral kynurenine pathway in rats. Pol. J. Environ. Stud. 14 (4), 501-507, 2005

Pawlak K., PAWLAK D., My┼Ťliwiec M.: Metoda terapii nerkozast─Öpczej a wybrane wska┼║niki stresu
oksydacyjnego i uszkodzenia ┼Ťr├│db┼éonka u pacjent├│w z przewlek┼é─ů niewydolno┼Ťci─ů nerek. Pol. Arch. Med.
Wewn. 113 (1), 21-26, 2005

Pawlak K., PAWLAK D., Mysliwiec M.: Cu/Zn superoxide dismutase plasma levels as a new useful clinical
biomarker of oxidative stress in patients with end-stage renal disease. Clin. Biochem. 38 (8), 700-705, 2005

Pawlak K., PAWLAK D., Mysliwiec M.: Circulating beta-chemokines and matrix metalloproteinase-9/tissue
inhibitor of metalloproteinase-1 system in hemodialyzed patients--role of oxidative stress. Cytokine 31 (1), 18-
24, 2005

2004 rok

Pawlak K., Naumnik B., Brz├│sko S., PAWLAK D., My┼Ťliwiec M.: Oxidative stress - a link between endothelial
injury, coagulation activation, and atherosclerosis in haemodialysis patients. Am. J. Nephrol. 24 (1), 154-161,
2004

Pawlak K., PAWLAK D., Mysliwiec M.: Hepatitis intensified oxidative stress, MIP-1beta and RANTES plasma
levels in uraemic patients. Cytokine 28 (6), 197-204, 2004

Pawlak K., PAWLAK D., Mysliwiec M.: Extrinsic coagulation pathway activation and metalloproteinase-2/TIMPs
system are related to oxidative stress and atherosclerosis in hemodialysis patients. Thromb. Haemost. 92 (3),
646-653, 2004

Pawlak S., PAWLAK D., Buczko W.: Wpływ hipoksji na regulację procesu erytropoezy - nowe spojrzenie. Przeg.
Lek. 61 (12), 1415-1419, 2004
Pawlak K., PAWLAK D., Mysliwiec M.: Possible new role of monocyte chemoattractant protein-1 in hemodialysis
patients with cardiovascular disease. Am. J. Nephrol. 24 (6), 635-640, 2004

Pawlak K., PAWLAK D., Mysliwiec M.: Oxidative stress influences CC-chemokine levels in hemodialyzed
patients. Nephron Physiol. 96 (4), 105-112, 2004

2003 rok

Tankiewicz A., PAWLAK D., Topczewska-Bruns J., Buczko W.: Kidney and liver kynurenine pathway enzymes in
chronic renal failure. Adv. Exp. Med. Biol. 527, 409-414, 2003

PAWLAK D., Koda M., Wo┼éczy┼äski S., My┼Ťliwiec M., Buczko W.: Mechanism of inhibitory effect of 3-
hydroxykynurenine on erythropoiesis in patients with renal insufficiency. Adv. Exp. Med. Biol. 527, 375-380,
2003
Topczewska-Bruns J., PAWLAK D., Tankiewicz A., Chabielska E., Buczko W.: Kynurenine metabolism in central
nervous system in experimental chronic renal failure. Adv. Exp. Med. Biol. 527, 177-182, 2003

PAWLAK D., Tankiewicz A., Matys T., Buczko W.: Peripheral distribution of kynurenine metabolites and activity of
kynurenine pathway enzymes in renal failure. J. Physiol. Pharmacol. 54, 175-189, 2003

PAWLAK D., Koda M., Pawlak S., Wołczyński S., Buczko W.: Contribution of quinolinic acid in the development of
anemia in renal insufficiency. Am. J. Physiol. Renal Physiol. 284, F693-700, 2003

2002 rok

Topczewska-Bruns J., PAWLAK D., Chabielska E., Tankiewicz A., Buczko W.: Increased levels of 3-
hydroxykynurenine in different brain regions of rats with chronic renal insufficiency. Brain Res. Bull. 58, 423-
428, 2002

Kucharewicz I., Pawlak R., Matys T., PAWLAK D., Buczko W.: Antithrombotic effect of captopril and losartan is
mediated by angiotensin-(1-7). Hypertension 40, 774-779, 2002

PAWLAK D., Tankiewicz A., My┼Ťliwiec P., Buczko W.: Tryptophan metabolism via the kynurenine pathway in
experimental chronic renal failure. Nephron 90, 328-335, 2002

My┼Ťliwiec P., PAWLAK D., My┼Ťliwiec M., Buczko W.: Endogenous neurotoxine - quinolinic acid is increased in
renal allograft recipients. Transp. Proc. 34, 598-600, 2002

Topczewska-Bruns J., PAWLAK D., Buczko W.: Modyfikacje szlaku kinureninowego ÔÇô nowe mo┼╝liwo┼Ťci leczenia
chor├│b OUN? Farm. Pol. 2, 51-56, 2002

2001 rok

Andrzejewska-Buczko J., PAWLAK D., Tankiewicz A., Matys T., Buczko W.: Possible involvement of
kynurenamines in the pathogenesis of cataract in diabetic patients. Med. Sci. Monit. 7, 742-745, 2001

Topczewska-Bruns J., Tankiewicz A., PAWLAK D., Buczko W.: Behavioral changes in the course of chronic renal
insufficiency in rats. Pol. J. Pharmacol. 53, 263-269, 2001

PAWLAK D., Tankiewicz A., Buczko W.: Kynurenine and its metabolites in the rat with experimental renal
insufficiency. J. Physiol. Pharmacol. 52, 755-766, 2001

PAWLAK D., Pawlak K., Ma┼éyszko J., My┼Ťliwiec M., Buczko W.: Accumulation of toxic products degradation of
kynurenine in hemodialyzed patients. Int. Urol. Nephrol. 33, 399-404, 2001

Tankiewicz A., PAWLAK D., Buczko W.: Enzymy szlaku kinureninowego. Post. Hig. Med. Do┼Ťw. 55, 715-731,
2001
2000 rok

Ma┼éyszko J.S., Ma┼éyszko J., Pawlak K., PAWLAK D., Buczko W., My┼Ťliwiec M.: Importance of serotonergic mechanisms in the thrombotic
complications in hemodialyzed patients treated with erythropoietin. Nephron 84, 305-311, 2000
Ma┼éyszko J.S., PAWLAK D., Ma┼éyszko J., Buczko W., My┼Ťliwiec M.: Peripheral serotonergic system in
hemodialyzed and peritoneally dialyzed patients. Nephron 86, 396-397, 2000

PAWLAK D., Takada Y., Urano T., Takada A.: Serotonergic and kynurenic pathways in rats exposed to foot
shock. Brain Res. Bull. 52, 197-205, 2000

PAWLAK D., Malczyk E., Darewicz J., Azzadin A., Buczko W.: Platelet serotonergic mechanisms in patients with
cancer of the urinary bladder. Thromb. Res. 2000 98, 367-374, 2000

Chabielska E., Matys T., Kucharwicz I., PAWLAK D., Rółkowski R., Buczko W.: The involvement of AT2-receptor
in the antithrombotic effect of losartan in renal hypertensive rats. J. Renin Angiotensin Aldosterone Syst. 1,
263-267, 2000

Kucharewicz I., Chabielska E., PAWLAK D., Matys T., Rółkowski R., Buczko W.: The anthithrombotic effect of
angiotensin-(1-7) closely resembles that of losartan. J. Renin Angiotensin Aldosterone Syst. 1, 268-272, 2000

My┼Ťliwiec P., PAWLAK D.: Szlak kinurenowy w zdrowiu i w chorobie. Post. Hig. Med. Do┼Ťw. 54, 239-252, 2000

1999 rok

Siwak E.B., PAWLAK D., Buczko W., Kondrusiuk M., Hermanowska- Szpakowicz T.: St─Ö┼╝enie serotoniny w
płynie mózgowo-rdzeniowym w przebiegu ropnych i kleszczowych zapaleń opon mózgowo-rdzeniowych i mózgu.
Neurol. Neurochir. Pol. 33, 339-349, 1999

1998 rok

PAWLAK D., Adamkiewicz M., Ma┼éyszko J., Takada A., My┼Ťliwiec M., Buczko W.: Vascular and cardiac effects of
DV-7028 - a selective, 5-HT2A receptor antagonist in rats. J. Cardiovasc. Pharmacol. 32, 266-273, 1998

PAWLAK D., Pawlak K., Chabielska E., Ma┼éyszko J., Takada A., My┼Ťliwiec M., Buczko W.: DV-7028, a potent 5-
hydroxytryptamine receptor (5-HT2A) antagonist delays arterial thrombosis development in rats. Thromb. Res. 90,
259-270, 1998

Chabielska E., Pawlak R., Golatowski R., Rółkowski R., PAWLAK D., Buczko W.: Losartan inhibits experimental
venous thrombosis in spontaneously hypertensive rats. Thromb. Res. 90, 271-278, 1998

Ma┼éyszko J.S., Ma┼éyszko J., PAWLAK D., Buczko W., My┼Ťliwiec M.: Hemostasis, platelet functions, serotonin and
serum lipids during omega-3 fatty acid treatmentin patients with glomerulonephritis. Nephron 80, 94-96, 1998

My┼Ťliwiec M., Ma┼éyszko J.S., Ma┼éyszko J., PAWLAK D., Buczko W.: Peripheral serotonergic mechanisms in
kidney diseases. Annal. Universit. M. Curie-Skłodowska Lublin-Polonia LII, 9-16, 1998

1997 rok

Łukaszewicz A., Markowski T., PAWLAK D.: Porównanie stężenia endogennego etanolu w surowicy krwi u
alkoholik├│w w r├│┼╝nym okresie abstynencji i u os├│b nie uzale┼╝nionych od alkoholu etylowego. Psychiatr. Pol. 31,
183-188, 1997

Kowal-Bielecka O., Bernacka K., PAWLAK D., Buczko W.: Serotonina a procesy immunologiczno-zapalne w
reumatoidalnym zapaleniu staw├│w. Reumatologia 35 (3), 329-338, 1997

Rydzewski A., Ma┼éyszko J., Borawski J., PAWLAK D., Azzadin A., Buczko W., My┼Ťliwiec M.: Altered circadian
rhythm of platelet aggregation in hemodialyzed patients. Nephron 77, 365-367, 1997

1996 rok

Ma┼éyszko J.S., Ma┼éyszko J., PAWLAK D., Pawlak K., My┼Ťliwiec M., Rydzewski A., Buczko W.: Comprehensive
study on platelet function, hemostasis, fibrinolysis, peripheral serotonergic system and serum lipids in nephrotic
syndrome. Pol. J. Pharmacol. 48, 191-195, 1996

Ma┼éyszko J., PAWLAK D., Ma┼éyszko J.S, Pawlak K., Buczko W., My┼Ťliwiec M.: Platelet aggregation and
peripheral serotonergic system in kidney transplant recipients treated with cyclosporine. Transplant. Proc. 28,
1956-1959, 1996
PAWLAK D., Ma┼éyszko J., Ma┼éyszko J.S., Pawlak K., Buczko W., My┼Ťliwiec M.: Peripheral serotonergic system in
uremia. Thromb. Res. 83, 189-194, 1996

Ma┼éyszko J., Ma┼éyszko J.S., PAWLAK D., Pawlak K., Buczko W., My┼Ťliwiec M.: Hemostasis, platelet function and
serotonin in acute and chronic renal failure. Thromb. Res. 83, 351-361, 1996

Andrzejewska-Buczko J., PAWLAK D., Walkowiak M., Stankiewicz A.: Serotonina w retinopatii cukrzycowej. Klin.
Oczna 98, 101-104, 1996

Telejko B., Kinalska I., PAWLAK D., Buczko W.: Platelet serotonergic mechanisms in patients with diabetes
medlitus and vascular complications. Pol. J. Endocrinol. 47, 65-71, 1996

Krygicz D., Azzadin A., Pawlak R., Ma┼éyszko J.S., PAWLAK D., My┼Ťliwiec M., Buczko W.: Cyclosporine A affects
serotonergic mechanisms in uremic rats. Pol. J. Pharmacol. 48, 351-354, 1996

PAWLAK D., Ma┼éyszko J., My┼Ťliwiec M., Takada A., Buczko W.: Effect of DV-7028, a novel serotonin 5-HT2
receptor antagonist on the cardiovascular system in rats. Acta Physiol. Hung. 84, 325-326, 1996

PAWLAK D., Ma┼éyszko J., My┼Ťliwiec M., Takada A., Buczko W.: Influence of MCI-9042, a novel 5-HT2 receptor
blocker on blood vessels on the rat. Acta Physiol. Hung. 84, 323-324, 1996

Filipowski T, PAWLAK D., Morelowska-Topczewska B., Buczko W.: Peripheral serotonergic mechanisms in the
cardiovascular system of epidermoid lung cancer patients. Acta Physiol. Hung. 84, 193-194, 1996

PAWLAK D., Malinowska B., Wollny T., Godlewski G., Buczko W.: Lack of the specific influence of histamine and
histamine H1, H2 and H3 receptor ligands on the serotonin uptake and release in blood platelets. Pol. J.
Pharmacol. 48, 615-620, 1996

1995 rok

Morelowska-Spierzak D., PAWLAK D., Buczko W.: Influence of captopril on the serotonin - induced vasopressor
effect in tail artery isolated from two - kidney, one clip renal hypertensive rats. Pol. J. Pharmacol. 47, 417-422,
1995

Di Girolamo M., Silletta M.G., De Matteis M.A., Braca A., Colnzi A., PAWLAK D., Rasenick M.M., Luini A., Corda
D.: Evidence that the 50 kDa substrate of brefeldin A - dependent ADP-ribosylation binds GTP and is modulated
by the G - protein ´üó´üž subunitcomplex. P. Natl. Acad. Sci. USA 92, 7065-7069, 1995

Ma┼éyszko J., Ma┼éyszko J.S., My┼Ťliwiec M., PAWLAK D., Buczko W.: Uk┼éad fibrynolizy i obwodowy uk┼éad
serotonergiczny u chorych z kłębuszkowym zapaleniem nerek. Przegl. Lek. 52, 428-430, 1995

1993 rok

PAWLAK D., Chabielska E., Buczko W.: Influence of acetaldehyde on some serotonergic mechanisms in rat
blood platelets. Pol. J. Pharmacol. 45, 59-66, 1993

PAWLAK D., Morelowska-Spierzak D., Azzadin A., Wr├│bel K., Buczko W.: Lack of effect of acetaldehyde on the
cardiovascular system in rats. Alcohol Alcoholism 28, 529-533, 1993

Buczko W., Malinowska B., Pietraszek M.H., PAWLAK D., Chabielska E.: Influence of Tolpa preparation on
haemostasis in rats. Acta Pol. Pharm. Drug Res. 50, 507-511,1993

Popławski A., Azzadin A., PAWLAK D., Buczko W., Kaliszewski Z.: Hamowanie procesu erytropoezy przez
ultrafiltrat uzyskany od chorych z kra┼äcow─ů niewydolno┼Ťci─ů nerek. Pol. Tyg. Lek. 50, 334-337, 1993

1992 rok

PAWLAK D., Malinowska B., Buczko W.: Cardiovascular effects of acetaldehyde in pithed rats. Pharmacology
45, 83-89, 1992

Azzadin A., Bia┼ékowska A., PAWLAK D., Chabielska E., Mazerska M., My┼Ťliwiec M., Buczko W.: Serotonin is
involved in some effects of erythropoietin. Thromb. Res. 65, 657-661, 1992
Malinowska B., PAWLAK D., Buczko W.: Influence of DAU 6215, a novel 5-HT3 receptor antagonist on the
cardiovascular system in anaesthetized and pithed rats. Agents Actions 36, 230-236, 1992

PAWLAK D., Krygicz D., Chabielska E., Buczko W.: Influence of acetaldehyde on vasopressor effect of serotonin
in pithed rats. Alcohol Alcoholism 27, 367-372, 1992

Buczko W., Malinowska B., Chabielska E., PAWLAK D.: Effect of ethanol on blood serotonergic mechanisms.
Hemostasis and Circulation A. Takada, A.Z. Budzynski Eds, Springer-Verlag, Tokyo, Berlin, Heidelberg, New
York, London, Paris, Hong Kong, Barcelona,133-138, 1992

Morelowska D., Chabielska E., PAWLAK D., Azzadin A., Krygicz D., Buczko W.: Effect of captopril on
serotonergic mechanisms in two-kidney, one-clip renal hypertensive rats. Pol. J. Pharmacol. 44, 365-372, 1992

1991 rok

Buczko W., Malinowska B., Chabielska E., PAWLAK D., Pietraszek M.: Udział mechanizmów serotoninergicznych
w dzia┼éaniu alkoholu etylowego na uk┼éad kr─ů┼╝enia szczura. Alkoholizm i Narkomania 57-66, 1991

1990 rok

Malinowska B., Pietraszek M., Chabielska E., PAWLAK D., Buczko W.: The effect of ethanol and serotonin on
blood vessels of the rat. Pol. J. Pharmacol. 42, 333-342, 1990

Malinowska B., PAWLAK D., Chabielska E., Buczko W.: Influence of acute and chronic ethanol administration on
the vasopressor effect of serotonin in pithed rats. Pharmacology 41, 91-97, 1990

1989 rok

Malinowska B., PAWLAK D., Chabielska E., Buczko W.: Cardiovascular effect of ethanol in anaesthetized,
concious and pithed rats. Drug Alcohol Depend. 24, 51-56, 1989